Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial

European Journal of Haematology
Norbert GattermannKALLISTO study investigators

Abstract

Erythropoiesis-stimulating agents (ESAs) remain first-choice to treat symptomatic anemia and delay transfusion dependence in most patients with lower-risk myelodysplastic syndromes (MDS) without del(5q). Deferasirox increased erythroid responses in some lower-risk MDS patients in clinical trials, and adding low-dose deferasirox to ESA treatment may further improve erythroid response. KALLISTO (NCT01868477) was a randomized, open-label, multicenter, phase II study. Lower-risk MDS patients received deferasirox at 10 mg/kg/d (dispersible tablets) or 7 mg/kg/d (film-coated tablets) plus erythropoietin (n = 11), or erythropoietin alone (n = 12) for 24 weeks. The primary endpoint was the between-group difference in erythroid response within 12 weeks. Erythroid response occurred in 27.3% of patients receiving deferasirox plus erythropoietin vs 41.7% of patients receiving erythropoietin alone within 12 weeks (difference 14.4%; 95% CI -24.0, 48.16). Within 24 weeks, the hematologic response rate was 27.3% with deferasirox plus erythropoietin vs 50% with erythropoietin alone, and hematologic improvement rates were 45.5% vs 100%. Deferasirox plus erythropoietin was generally well tolerated. In this small pilot study, combining low-dose de...Continue Reading

References

Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
Oct 17, 2008·Experimental Hematology·Steve ElliottIain C Macdougall
Sep 22, 2009·British Journal of Haematology·Giuliana ZanninelliZvi I Cabantchik
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan F ListEmmanuel Besa

❮ Previous
Next ❯

Citations

Jun 2, 2020·Expert Review of Anticancer Therapy·Jonathan FeldShyamala C Navada
Jul 30, 2019·Expert Review of Hematology·Ulrich GermingNorbert Gattermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.